First Tracks Biotherapeutics, Inc. (NasdaqGS: TRAX)
Health Care · Biotechnology · US
$44.04
-2.85% today · +131.8% 1Y
First Tracks Biotherapeutics, Inc. (NasdaqGS: TRAX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.57B and employs 104 people.
Over the last twelve months the share price has gained 131.8%, trading between 14.72 and 49.58.
TRAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.57B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.85
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $49.58
- 52-week low
- $14.72
- Avg volume (3M)
- —
- Shares outstanding
- 35.73M
- Employees
- 104
- Next earnings
- —
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
- Founded
- 2019
- Listed since
- Apr 20, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.